Table 5. Paediatric death (fetal, neonatal, or later death) at any time* (all trials).
| Trial | MgSO4 | Control | Relative risk | 95% confidence interval |
|---|---|---|---|---|
| ACTOMgSO4 [9] | 87/629 (13.8%) | 108/626 (17.3%) | 0.81 | 0.62–1.07 |
| PREMAG [10] | 34/353 (9.6%) | 38/338 (11.2%) | 0.83 | 0.52–1.32 |
| MAGNET [11] | 10/86 (11.6%) | 1/80 (1.3%) | 8.11 | 1.05–62.69 |
| MAGPIE [12] | 200/790 (25.3%) | 177/785 (22.5%) | 1.09 | 0.91–1.30 |
| BEAM‡ [13] | 105/1,188 (8.8%) | 97/1,256 (7.7%) | 1.15 | 0.88–1.51 |
| Overall† | 436/3,046 (14.3%) | 421/3,085 (13.6%) | 1.03 | 0.91–1.17 |
Abbreviations: ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulphate; BEAM, Beneficial Effects of Antenatal Magnesium Sulfate; MAGNET, Magnesium and Neurologic Endpoints Trial; MAGPIE, MAGnesium sulphate for Prevention of Eclampsia; MgSO4, magnesium sulphate; PREMAG, PREterm brain protection by MAGnesium sulphate.
*Available data.
‡The BEAM trial only recorded deaths in the first 12 months of life
†p-value for heterogeneity = 0.07 (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and trial in a generalising estimating equation [GEE] model).